Literature DB >> 3705006

Heparin-associated thrombocytopenia treatment with low molecular weight heparin.

J F Vitoux, J F Mathieu, M Roncato, J N Fiessinger, M Aiach.   

Abstract

Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3705006

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


  5 in total

1.  Heparin-induced thrombocytopenia and thrombosis with spinal ischaemia--recovery of platelet count following a change to a low molecular weight heparin.

Authors:  N Maurin; R Biniek; B Heintz; H Kierdorf
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 2.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 4.  Manipulation of coagulation factors in acute stroke.

Authors:  J F Meschia; J Biller
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.